Good morning, myeloma world.

It truly was a dark and stormy night when we sat down early yesterday to start writing the next edition of Myeloma Morning. A spring windstorm was howling about outside and, before we knew it, the wily gusts had conspired to knock out electricity at Myeloma Morning Headquarters.

Fortunately, the watts and volts are back in working order, and we're glad to be writing for you again.

All the news we cover in today's

As I mentioned in my pre­vi­ous column, I started treat­ment with the newly approved myeloma drug Empliciti (elo­tuzu­mab) in Feb­ru­ary. I thought I would share more details about my ex­peri­ences with the drug so far.

Before I started treat­ment with Empliciti, I had enjoyed a drug holiday for the pre­vi­ous three months. I ap­pre­ci­ated the break from the side effects of drugs and nu­mer­ous trips to the cancer center.

Before the drug holiday, I was on

A belated good morning to you, myeloma world.

How has your Friday been so far? Has April Fools' Day brought joy, con­ster­na­tion, or a bit of both to your life?

We were caught off guard this morning by some news that came out just as we were about to wrap up this edition of Myeloma Morning. But the news, which con­cerns Darzalex, is good, so we definitely won't be com­plaining.

Here are today's myeloma-related headlines.

First, Darzalex (daratumuab) is …

Good morning, myeloma world.

We all should have seen this coming.

After days and days of having no major myeloma business news to cover here at Myeloma Morning, what hap­pens? Suddenly, there's not just one new myeloma-related business devel­op­ment to discuss. And not just two. But a full three such news items to review.

So let's start with those devel­op­ments, after which we'll take a quick look at a new research article and what's been going on …

Good morning, myeloma world.

We have a slightly different edition of Myeloma Morning cooked up for you today than is usually the case. Although we have one new myeloma research study that we will review – see the discussion further below about Cometriq – we will spend most of today's edition looking in more detail at an issue discussed in this Monday's edition of Myeloma Morning.

In that article, we discussed a recent study by physicians at the …

Have you ever really thought about the differences between symptomatic myeloma and smoldering myeloma?

If you ask newly diagnosed patients about their symptomatic myeloma, you’ll likely hear stories with common themes – like “we’re hitting the myeloma hard,” and how the treatment was scheduled with a sense of urgency. This type of myeloma usually has patients and their specialists leaping into action in hopes of bringing a quick and lasting remission. Of course, symptomatic multiple myeloma is an active disease with …

Good morning, myeloma world.

It's a glorious spring morning here at Myeloma Morning Headquarters. The sun is coming up in the midst of a clear blue sky, and the cherry tree out front is bursting with blossoms.

In other words, it's a great day to get excited about new multiple myeloma research and other myeloma-related developments.

First, we take a look at a new study by researchers at the John Theurer Cancer Center (JTCC) in New Jersey. They examine whether …